Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies
| Autor: | Ian R. Friedland, Guillermo Ortiz-Ruiz, Norbert Vetter, Alexandra D. Carides, Robin Isaacs, Gail L. Woods |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Ertapenem Male Microbiology (medical) medicine.medical_specialty Adolescent Lactams Pneumonia severity index Gram-Positive Bacteria beta-Lactams chemistry.chemical_compound Double-Blind Method Community-acquired pneumonia Internal medicine Gram-Negative Bacteria Pneumonia Bacterial medicine Humans Pharmacology (medical) Child Adverse effect Aged Antibacterial agent Pharmacology business.industry Ceftriaxone Middle Aged medicine.disease Anti-Bacterial Agents Surgery Community-Acquired Infections Penicillin Pneumonia Treatment Outcome Infectious Diseases chemistry Child Preschool Female business medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 53:ii59-ii66 |
| ISSN: | 1460-2091 |
| DOI: | 10.1093/jac/dkh207 |
| Popis: | The efficacy and safety of ertapenem, 1 g once a day, for the treatment of community-acquired pneumonia (CAP) requiring parenteral therapy were compared with those of ceftriaxone, 1 g once a day, in 866 hospitalized adults randomized in two prospective, double-blind, multicentre studies. Patients were stratified according to Pneumonia Severity Index (or = 3 or3) or age (or = 65 or65 years). Afteror = 3 days of parenteral antimicrobial therapy, patients who had clinically improved could be switched to oral co-amoxiclav. The median durations of parenteral, oral and total therapy in the 658 clinically evaluable patients, of whom 88% were switched to oral therapy, were 4, 7 and 12 days, respectively, in both treatment groups. The most common pathogen was Streptococcus pneumoniae, of which 79% (143/181) were penicillin susceptible and 3.3% (6/181; three in each treatment group) were penicillin resistant. Cure rates for the two treatments were equivalent: 91.9% for ertapenem and 92.0% for ceftriaxone (95% confidence interval for the difference, adjusted for strata: -4.5 to 4.4). Cure rates in the different severity and age strata and bacterial eradication rates for both treatment groups were also similar. The most common drug-related adverse events in both treatment groups were diarrhoea and mild-to-moderate elevations in aminotransferase levels. The results of these studies demonstrate that ertapenem, 1 g once a day, was highly effective therapy for CAP in hospitalized adults with moderate-to-severe disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|